JP2008510763A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008510763A5 JP2008510763A5 JP2007528754A JP2007528754A JP2008510763A5 JP 2008510763 A5 JP2008510763 A5 JP 2008510763A5 JP 2007528754 A JP2007528754 A JP 2007528754A JP 2007528754 A JP2007528754 A JP 2007528754A JP 2008510763 A5 JP2008510763 A5 JP 2008510763A5
- Authority
- JP
- Japan
- Prior art keywords
- ylamino
- methoxy
- pyrimidin
- phenylamino
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 56
- 125000000623 heterocyclic group Chemical group 0.000 claims description 39
- 229910052739 hydrogen Inorganic materials 0.000 claims description 35
- 239000001257 hydrogen Substances 0.000 claims description 35
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 27
- 125000003545 alkoxy group Chemical group 0.000 claims description 21
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 17
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 16
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 14
- 125000006413 ring segment Chemical group 0.000 claims description 14
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 11
- 125000003282 alkyl amino group Chemical group 0.000 claims description 10
- 150000002431 hydrogen Chemical class 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 3
- 241001024304 Mino Species 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 3
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims 16
- 150000001408 amides Chemical class 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 238000000034 method Methods 0.000 claims 4
- 208000026278 immune system disease Diseases 0.000 claims 3
- 230000001613 neoplastic effect Effects 0.000 claims 3
- XZYWSQJGDNNNTA-UHFFFAOYSA-N 2-[[5-bromo-2-(2-methoxy-5-morpholin-4-ylanilino)pyrimidin-4-yl]amino]-n,n-dimethylbenzenesulfonamide Chemical compound COC1=CC=C(N2CCOCC2)C=C1NC(N=1)=NC=C(Br)C=1NC1=CC=CC=C1S(=O)(=O)N(C)C XZYWSQJGDNNNTA-UHFFFAOYSA-N 0.000 claims 2
- CVICEEPAFUYBJG-UHFFFAOYSA-N 5-chloro-2,2-difluoro-1,3-benzodioxole Chemical group C1=C(Cl)C=C2OC(F)(F)OC2=C1 CVICEEPAFUYBJG-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940088679 drug related substance Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- QNZSRUNDCIMEQW-HHHXNRCGSA-N (3r)-1-[4-[[5-chloro-4-[(2-methyl-3-oxo-1h-isoindol-4-yl)amino]pyrimidin-2-yl]amino]-3-methoxyphenyl]-3-methylpiperidine-3-carboxamide Chemical compound C=1C=C(NC=2N=C(NC=3C=4C(=O)N(C)CC=4C=CC=3)C(Cl)=CN=2)C(OC)=CC=1N1CCC[C@@](C)(C(N)=O)C1 QNZSRUNDCIMEQW-HHHXNRCGSA-N 0.000 claims 1
- NIDGJESNBXPTJZ-AREMUKBSSA-N (3r)-1-[4-[[5-chloro-4-[2-(methylcarbamoyl)anilino]pyrimidin-2-yl]amino]-3-methoxyphenyl]-3-methylpiperidine-3-carboxamide Chemical compound CNC(=O)C1=CC=CC=C1NC1=NC(NC=2C(=CC(=CC=2)N2C[C@@](C)(CCC2)C(N)=O)OC)=NC=C1Cl NIDGJESNBXPTJZ-AREMUKBSSA-N 0.000 claims 1
- QNZSRUNDCIMEQW-MHZLTWQESA-N (3s)-1-[4-[[5-chloro-4-[(2-methyl-3-oxo-1h-isoindol-4-yl)amino]pyrimidin-2-yl]amino]-3-methoxyphenyl]-3-methylpiperidine-3-carboxamide Chemical compound C=1C=C(NC=2N=C(NC=3C=4C(=O)N(C)CC=4C=CC=3)C(Cl)=CN=2)C(OC)=CC=1N1CCC[C@](C)(C(N)=O)C1 QNZSRUNDCIMEQW-MHZLTWQESA-N 0.000 claims 1
- NIDGJESNBXPTJZ-SANMLTNESA-N (3s)-1-[4-[[5-chloro-4-[2-(methylcarbamoyl)anilino]pyrimidin-2-yl]amino]-3-methoxyphenyl]-3-methylpiperidine-3-carboxamide Chemical compound CNC(=O)C1=CC=CC=C1NC1=NC(NC=2C(=CC(=CC=2)N2C[C@](C)(CCC2)C(N)=O)OC)=NC=C1Cl NIDGJESNBXPTJZ-SANMLTNESA-N 0.000 claims 1
- -1 1,2,2,6,6-pentamethyl-piperidin-4-yloxy Chemical group 0.000 claims 1
- QNZSRUNDCIMEQW-UHFFFAOYSA-N 1-[4-[[5-chloro-4-[(2-methyl-3-oxo-1h-isoindol-4-yl)amino]pyrimidin-2-yl]amino]-3-methoxyphenyl]-3-methylpiperidine-3-carboxamide Chemical compound C=1C=C(NC=2N=C(NC=3C=4C(=O)N(C)CC=4C=CC=3)C(Cl)=CN=2)C(OC)=CC=1N1CCCC(C)(C(N)=O)C1 QNZSRUNDCIMEQW-UHFFFAOYSA-N 0.000 claims 1
- ZMRTULLVSRWTIK-UHFFFAOYSA-N 1-[4-[[5-chloro-4-[(2-methyl-3-oxo-1h-isoindol-4-yl)amino]pyrimidin-2-yl]amino]-3-methoxyphenyl]piperidine-3-carboxamide Chemical compound C=1C=C(NC=2N=C(NC=3C=4C(=O)N(C)CC=4C=CC=3)C(Cl)=CN=2)C(OC)=CC=1N1CCCC(C(N)=O)C1 ZMRTULLVSRWTIK-UHFFFAOYSA-N 0.000 claims 1
- HRLQTDYPYJAQKB-UHFFFAOYSA-N 1-[4-[[5-chloro-4-[(2-methyl-3-oxo-1h-isoindol-4-yl)amino]pyrimidin-2-yl]amino]-3-methoxyphenyl]piperidine-4-carboxamide Chemical compound C=1C=C(NC=2N=C(NC=3C=4C(=O)N(C)CC=4C=CC=3)C(Cl)=CN=2)C(OC)=CC=1N1CCC(C(N)=O)CC1 HRLQTDYPYJAQKB-UHFFFAOYSA-N 0.000 claims 1
- SSMJKMUSHJBJIT-UHFFFAOYSA-N 1-[4-[[5-chloro-4-[2-(2-methylpropylsulfamoyl)anilino]pyrimidin-2-yl]amino]-3-methoxyphenyl]-3-methylpiperidine-3-carboxamide Chemical compound COC1=CC(N2CC(C)(CCC2)C(N)=O)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1S(=O)(=O)NCC(C)C SSMJKMUSHJBJIT-UHFFFAOYSA-N 0.000 claims 1
- PRYRRVRTLNGSJO-UHFFFAOYSA-N 1-[4-[[5-chloro-4-[2-(2-methylpropylsulfamoyl)anilino]pyrimidin-2-yl]amino]-3-methoxyphenyl]piperidine-4-carboxamide Chemical compound COC1=CC(N2CCC(CC2)C(N)=O)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1S(=O)(=O)NCC(C)C PRYRRVRTLNGSJO-UHFFFAOYSA-N 0.000 claims 1
- NIDGJESNBXPTJZ-UHFFFAOYSA-N 1-[4-[[5-chloro-4-[2-(methylcarbamoyl)anilino]pyrimidin-2-yl]amino]-3-methoxyphenyl]-3-methylpiperidine-3-carboxamide Chemical compound CNC(=O)C1=CC=CC=C1NC1=NC(NC=2C(=CC(=CC=2)N2CC(C)(CCC2)C(N)=O)OC)=NC=C1Cl NIDGJESNBXPTJZ-UHFFFAOYSA-N 0.000 claims 1
- BSAXWMSAVVOOHO-UHFFFAOYSA-N 2,2-dioxo-1,5-dihydroimidazo[4,5-c][1,2,6]thiadiazin-4-one Chemical compound O=C1NS(=O)(=O)NC2=C1NC=N2 BSAXWMSAVVOOHO-UHFFFAOYSA-N 0.000 claims 1
- VGNZWQKJQOQQDO-UHFFFAOYSA-N 2-(2-methoxy-4-morpholin-4-ylphenyl)-1H-pyrimidine-2,4-diamine Chemical compound COC1=C(C=CC(=C1)N1CCOCC1)C1(NC=CC(=N1)N)N VGNZWQKJQOQQDO-UHFFFAOYSA-N 0.000 claims 1
- YGIKNSYRWWYNEM-UHFFFAOYSA-N 2-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-1H-pyrimidine-2,4-diamine Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1C1(N)NC=CC(N)=N1 YGIKNSYRWWYNEM-UHFFFAOYSA-N 0.000 claims 1
- ZCHNJFUSZJSLQX-UHFFFAOYSA-N 2-[[5-bromo-2-(2,4-dimethoxy-5-morpholin-4-ylanilino)pyrimidin-4-yl]amino]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1NC1=NC(NC=2C(=CC(OC)=C(N3CCOCC3)C=2)OC)=NC=C1Br ZCHNJFUSZJSLQX-UHFFFAOYSA-N 0.000 claims 1
- PCPYKCXGYNSQDW-UHFFFAOYSA-N 2-[[5-bromo-2-(2,4-dimethoxy-5-morpholin-4-ylanilino)pyrimidin-4-yl]amino]-n-propan-2-ylbenzenesulfonamide Chemical compound COC1=CC(OC)=C(N2CCOCC2)C=C1NC(N=1)=NC=C(Br)C=1NC1=CC=CC=C1S(=O)(=O)NC(C)C PCPYKCXGYNSQDW-UHFFFAOYSA-N 0.000 claims 1
- JPOWYEVZJLBENT-UHFFFAOYSA-N 2-[[5-bromo-2-(2,5-dimethoxy-4-morpholin-4-ylanilino)pyrimidin-4-yl]amino]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1NC1=NC(NC=2C(=CC(=C(OC)C=2)N2CCOCC2)OC)=NC=C1Br JPOWYEVZJLBENT-UHFFFAOYSA-N 0.000 claims 1
- YBQXFJXKEHAULY-UHFFFAOYSA-N 2-[[5-bromo-2-(2-methoxy-5-morpholin-4-ylanilino)pyrimidin-4-yl]amino]-n-propan-2-ylbenzenesulfonamide Chemical compound COC1=CC=C(N2CCOCC2)C=C1NC(N=1)=NC=C(Br)C=1NC1=CC=CC=C1S(=O)(=O)NC(C)C YBQXFJXKEHAULY-UHFFFAOYSA-N 0.000 claims 1
- DLTCCPJCILRITC-UHFFFAOYSA-N 2-[[5-bromo-2-(2-methoxy-5-piperidin-1-ylanilino)pyrimidin-4-yl]amino]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1NC1=NC(NC=2C(=CC=C(C=2)N2CCCCC2)OC)=NC=C1Br DLTCCPJCILRITC-UHFFFAOYSA-N 0.000 claims 1
- LCPYQOSIVUZMTL-UHFFFAOYSA-N 2-[[5-bromo-2-(2-methoxy-5-piperidin-1-ylanilino)pyrimidin-4-yl]amino]-n-propan-2-ylbenzenesulfonamide Chemical compound COC1=CC=C(N2CCCCC2)C=C1NC(N=1)=NC=C(Br)C=1NC1=CC=CC=C1S(=O)(=O)NC(C)C LCPYQOSIVUZMTL-UHFFFAOYSA-N 0.000 claims 1
- XSXSLHFJXLBSAI-UHFFFAOYSA-N 2-[[5-bromo-2-(4-fluoro-2-methoxy-5-morpholin-4-ylanilino)pyrimidin-4-yl]amino]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1NC1=NC(NC=2C(=CC(F)=C(N3CCOCC3)C=2)OC)=NC=C1Br XSXSLHFJXLBSAI-UHFFFAOYSA-N 0.000 claims 1
- SGFZYDWNVCEVJU-UHFFFAOYSA-N 2-[[5-bromo-2-[(7-methoxy-4-methyl-3-oxo-1,4-benzoxazin-6-yl)amino]pyrimidin-4-yl]amino]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1NC1=NC(NC=2C(=CC=3OCC(=O)N(C)C=3C=2)OC)=NC=C1Br SGFZYDWNVCEVJU-UHFFFAOYSA-N 0.000 claims 1
- UWGHABCNOXARNC-UHFFFAOYSA-N 2-[[5-bromo-2-[2,4-dimethoxy-5-(2-morpholin-4-ylethoxy)anilino]pyrimidin-4-yl]amino]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1NC1=NC(NC=2C(=CC(OC)=C(OCCN3CCOCC3)C=2)OC)=NC=C1Br UWGHABCNOXARNC-UHFFFAOYSA-N 0.000 claims 1
- MEDZUBFZDSXJAC-UHFFFAOYSA-N 2-[[5-bromo-2-[2-methoxy-5-(1-methylpiperidin-4-yl)oxyanilino]pyrimidin-4-yl]amino]-n-propan-2-ylbenzenesulfonamide Chemical compound C1=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)NC(C)C)C(Br)=CN=2)C(OC)=CC=C1OC1CCN(C)CC1 MEDZUBFZDSXJAC-UHFFFAOYSA-N 0.000 claims 1
- ITKGHUPAYWHBIP-UHFFFAOYSA-N 2-[[5-bromo-2-[2-methoxy-5-(1-propan-2-ylpiperidin-4-yl)oxyanilino]pyrimidin-4-yl]amino]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1NC1=NC(NC=2C(=CC=C(OC3CCN(CC3)C(C)C)C=2)OC)=NC=C1Br ITKGHUPAYWHBIP-UHFFFAOYSA-N 0.000 claims 1
- XLZBPRVOHGJWAJ-UHFFFAOYSA-N 2-[[5-bromo-2-[2-methoxy-5-(1-propan-2-ylpiperidin-4-yl)oxyanilino]pyrimidin-4-yl]amino]-n-propan-2-ylbenzenesulfonamide Chemical compound C1=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)NC(C)C)C(Br)=CN=2)C(OC)=CC=C1OC1CCN(C(C)C)CC1 XLZBPRVOHGJWAJ-UHFFFAOYSA-N 0.000 claims 1
- YOTZCSJSLZPECF-UHFFFAOYSA-N 2-[[5-bromo-2-[2-methoxy-5-(2-morpholin-4-ylethoxy)anilino]pyrimidin-4-yl]amino]-n,n-dimethylbenzenesulfonamide Chemical compound C1=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)N(C)C)C(Br)=CN=2)C(OC)=CC=C1OCCN1CCOCC1 YOTZCSJSLZPECF-UHFFFAOYSA-N 0.000 claims 1
- BCYMTKQQVMDBNP-UHFFFAOYSA-N 2-[[5-bromo-2-[2-methoxy-5-(2-morpholin-4-ylethoxy)anilino]pyrimidin-4-yl]amino]-n-propan-2-ylbenzenesulfonamide Chemical compound C1=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)NC(C)C)C(Br)=CN=2)C(OC)=CC=C1OCCN1CCOCC1 BCYMTKQQVMDBNP-UHFFFAOYSA-N 0.000 claims 1
- JJEBJAFGKXTQHS-UHFFFAOYSA-N 2-[[5-bromo-2-[2-methoxy-5-(2-piperidin-1-ylethoxy)anilino]pyrimidin-4-yl]amino]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1NC1=NC(NC=2C(=CC=C(OCCN3CCCCC3)C=2)OC)=NC=C1Br JJEBJAFGKXTQHS-UHFFFAOYSA-N 0.000 claims 1
- NREPZYCCHRXIMV-UHFFFAOYSA-N 2-[[5-bromo-2-[2-methoxy-5-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]-n-propan-2-ylbenzenesulfonamide Chemical compound COC1=CC=C(N2CCN(C)CC2)C=C1NC(N=1)=NC=C(Br)C=1NC1=CC=CC=C1S(=O)(=O)NC(C)C NREPZYCCHRXIMV-UHFFFAOYSA-N 0.000 claims 1
- WEOPBMCHEOLQJO-UHFFFAOYSA-N 2-[[5-bromo-2-[2-methoxy-5-(4-morpholin-4-ylpiperidin-1-yl)anilino]pyrimidin-4-yl]amino]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1NC1=NC(NC=2C(=CC=C(C=2)N2CCC(CC2)N2CCOCC2)OC)=NC=C1Br WEOPBMCHEOLQJO-UHFFFAOYSA-N 0.000 claims 1
- NMLYDTMONIHLGL-UHFFFAOYSA-N 2-[[5-bromo-2-[2-methoxy-5-(4-morpholin-4-ylpiperidin-1-yl)anilino]pyrimidin-4-yl]amino]-n-propan-2-ylbenzenesulfonamide Chemical compound COC1=CC=C(N2CCC(CC2)N2CCOCC2)C=C1NC(N=1)=NC=C(Br)C=1NC1=CC=CC=C1S(=O)(=O)NC(C)C NMLYDTMONIHLGL-UHFFFAOYSA-N 0.000 claims 1
- BQKXLUBHBKXGFL-UHFFFAOYSA-N 2-[[5-bromo-2-[2-methoxy-5-(4-piperidin-1-ylpiperidin-1-yl)anilino]pyrimidin-4-yl]amino]-n-propan-2-ylbenzenesulfonamide Chemical compound COC1=CC=C(N2CCC(CC2)N2CCCCC2)C=C1NC(N=1)=NC=C(Br)C=1NC1=CC=CC=C1S(=O)(=O)NC(C)C BQKXLUBHBKXGFL-UHFFFAOYSA-N 0.000 claims 1
- WBZMQZPBJXOQBL-UHFFFAOYSA-N 2-[[5-bromo-2-[2-methoxy-5-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]pyrimidin-4-yl]amino]-n,n-dimethylbenzenesulfonamide Chemical compound COC1=CC=C(N2CCC(CC2)N2CCN(C)CC2)C=C1NC(N=1)=NC=C(Br)C=1NC1=CC=CC=C1S(=O)(=O)N(C)C WBZMQZPBJXOQBL-UHFFFAOYSA-N 0.000 claims 1
- KNFGKRUZBFUTFB-UHFFFAOYSA-N 2-[[5-bromo-2-[2-methoxy-5-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]pyrimidin-4-yl]amino]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1NC1=NC(NC=2C(=CC=C(C=2)N2CCC(CC2)N2CCN(C)CC2)OC)=NC=C1Br KNFGKRUZBFUTFB-UHFFFAOYSA-N 0.000 claims 1
- JSDVQDPZXCMQDL-UHFFFAOYSA-N 2-[[5-bromo-2-[2-methoxy-5-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]pyrimidin-4-yl]amino]-n-propan-2-ylbenzenesulfonamide Chemical compound COC1=CC=C(N2CCC(CC2)N2CCN(C)CC2)C=C1NC(N=1)=NC=C(Br)C=1NC1=CC=CC=C1S(=O)(=O)NC(C)C JSDVQDPZXCMQDL-UHFFFAOYSA-N 0.000 claims 1
- AGZKTTMKEHBTCY-INIZCTEOSA-N 2-[[5-bromo-2-[2-methoxy-5-[[(2s)-1-methylpyrrolidin-2-yl]methoxy]anilino]pyrimidin-4-yl]amino]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1NC1=NC(NC=2C(=CC=C(OC[C@H]3N(CCC3)C)C=2)OC)=NC=C1Br AGZKTTMKEHBTCY-INIZCTEOSA-N 0.000 claims 1
- MTAXVMSPLTYQDA-UHFFFAOYSA-N 2-[[5-bromo-2-[5-(4-hydroxypiperidin-1-yl)-2-methoxyanilino]pyrimidin-4-yl]amino]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1NC1=NC(NC=2C(=CC=C(C=2)N2CCC(O)CC2)OC)=NC=C1Br MTAXVMSPLTYQDA-UHFFFAOYSA-N 0.000 claims 1
- MUZJZFBDMABTNL-UHFFFAOYSA-N 2-[[5-bromo-2-[5-(4-hydroxypiperidin-1-yl)-2-methoxyanilino]pyrimidin-4-yl]amino]-n-propan-2-ylbenzenesulfonamide Chemical compound COC1=CC=C(N2CCC(O)CC2)C=C1NC(N=1)=NC=C(Br)C=1NC1=CC=CC=C1S(=O)(=O)NC(C)C MUZJZFBDMABTNL-UHFFFAOYSA-N 0.000 claims 1
- OXWWVQIXMROYLT-UHFFFAOYSA-N 2-[[5-bromo-2-[5-[2-(4-hydroxypiperidin-1-yl)ethoxy]-2-methoxyanilino]pyrimidin-4-yl]amino]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1NC1=NC(NC=2C(=CC=C(OCCN3CCC(O)CC3)C=2)OC)=NC=C1Br OXWWVQIXMROYLT-UHFFFAOYSA-N 0.000 claims 1
- FOODYKIABZLSCE-UHFFFAOYSA-N 2-[[5-bromo-2-[5-[3-(dimethylamino)pyrrolidin-1-yl]-2-methoxyanilino]pyrimidin-4-yl]amino]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1NC1=NC(NC=2C(=CC=C(C=2)N2CC(CC2)N(C)C)OC)=NC=C1Br FOODYKIABZLSCE-UHFFFAOYSA-N 0.000 claims 1
- WWRSLSFQDJKUAL-UHFFFAOYSA-N 2-[[5-bromo-2-[5-[3-(dimethylamino)pyrrolidin-1-yl]-2-methoxyanilino]pyrimidin-4-yl]amino]-n-propan-2-ylbenzenesulfonamide Chemical compound COC1=CC=C(N2CC(CC2)N(C)C)C=C1NC(N=1)=NC=C(Br)C=1NC1=CC=CC=C1S(=O)(=O)NC(C)C WWRSLSFQDJKUAL-UHFFFAOYSA-N 0.000 claims 1
- VBOFRRPQWRDUBS-UHFFFAOYSA-N 2-[[5-chloro-2-(2-methoxy-4-morpholin-4-ylanilino)pyrimidin-4-yl]amino]-5-(4-hydroxypiperidin-1-yl)-n-methylbenzamide Chemical compound CNC(=O)C1=CC(N2CCC(O)CC2)=CC=C1NC(C(=CN=1)Cl)=NC=1NC(C(=C1)OC)=CC=C1N1CCOCC1 VBOFRRPQWRDUBS-UHFFFAOYSA-N 0.000 claims 1
- GUQUCLOOXRBTBR-NRFANRHFSA-N 2-[[5-chloro-2-(2-methoxy-4-morpholin-4-ylanilino)pyrimidin-4-yl]amino]-5-[(3s)-3-(dimethylamino)pyrrolidin-1-yl]-n-methylbenzamide Chemical compound CNC(=O)C1=CC(N2C[C@H](CC2)N(C)C)=CC=C1NC(C(=CN=1)Cl)=NC=1NC(C(=C1)OC)=CC=C1N1CCOCC1 GUQUCLOOXRBTBR-NRFANRHFSA-N 0.000 claims 1
- BJSYJIMZQJENEB-UHFFFAOYSA-N 2-[[5-chloro-2-(2-methoxy-4-morpholin-4-ylanilino)pyrimidin-4-yl]amino]-n-(2,2-dimethylpropyl)benzenesulfonamide Chemical compound COC1=CC(N2CCOCC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1S(=O)(=O)NCC(C)(C)C BJSYJIMZQJENEB-UHFFFAOYSA-N 0.000 claims 1
- LHOIBMDNIPXEGW-UHFFFAOYSA-N 2-[[5-chloro-2-(2-methoxy-4-morpholin-4-ylanilino)pyrimidin-4-yl]amino]-n-(2-ethoxyethyl)benzenesulfonamide Chemical compound CCOCCNS(=O)(=O)C1=CC=CC=C1NC1=NC(NC=2C(=CC(=CC=2)N2CCOCC2)OC)=NC=C1Cl LHOIBMDNIPXEGW-UHFFFAOYSA-N 0.000 claims 1
- ZJAYIJSMCXWANH-UHFFFAOYSA-N 2-[[5-chloro-2-(2-methoxy-4-morpholin-4-ylanilino)pyrimidin-4-yl]amino]-n-(2-hydroxyethyl)benzenesulfonamide Chemical compound COC1=CC(N2CCOCC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1S(=O)(=O)NCCO ZJAYIJSMCXWANH-UHFFFAOYSA-N 0.000 claims 1
- JYDHDWVCAXMOSC-UHFFFAOYSA-N 2-[[5-chloro-2-(2-methoxy-4-morpholin-4-ylanilino)pyrimidin-4-yl]amino]-n-(2-methoxyethyl)benzenesulfonamide Chemical compound COCCNS(=O)(=O)C1=CC=CC=C1NC1=NC(NC=2C(=CC(=CC=2)N2CCOCC2)OC)=NC=C1Cl JYDHDWVCAXMOSC-UHFFFAOYSA-N 0.000 claims 1
- GAUIPSIHBYNJAD-UHFFFAOYSA-N 2-[[5-chloro-2-(2-methoxy-4-morpholin-4-ylanilino)pyrimidin-4-yl]amino]-n-(3-hydroxypropyl)benzenesulfonamide Chemical compound COC1=CC(N2CCOCC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1S(=O)(=O)NCCCO GAUIPSIHBYNJAD-UHFFFAOYSA-N 0.000 claims 1
- XBJSNLHFYPKXLS-MRXNPFEDSA-N 2-[[5-chloro-2-(2-methoxy-4-morpholin-4-ylanilino)pyrimidin-4-yl]amino]-n-[(2r)-2-hydroxypropyl]benzenesulfonamide Chemical compound COC1=CC(N2CCOCC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1S(=O)(=O)NC[C@@H](C)O XBJSNLHFYPKXLS-MRXNPFEDSA-N 0.000 claims 1
- XBJSNLHFYPKXLS-INIZCTEOSA-N 2-[[5-chloro-2-(2-methoxy-4-morpholin-4-ylanilino)pyrimidin-4-yl]amino]-n-[(2s)-2-hydroxypropyl]benzenesulfonamide Chemical compound COC1=CC(N2CCOCC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1S(=O)(=O)NC[C@H](C)O XBJSNLHFYPKXLS-INIZCTEOSA-N 0.000 claims 1
- UIAFSUJLLIGOQU-UHFFFAOYSA-N 2-[[5-chloro-2-(2-methoxy-4-morpholin-4-ylanilino)pyrimidin-4-yl]amino]-n-[2-(dimethylamino)ethyl]benzenesulfonamide Chemical compound COC1=CC(N2CCOCC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1S(=O)(=O)NCCN(C)C UIAFSUJLLIGOQU-UHFFFAOYSA-N 0.000 claims 1
- FJALCYJVUXODQN-UHFFFAOYSA-N 2-[[5-chloro-2-(2-methoxy-4-morpholin-4-ylanilino)pyrimidin-4-yl]amino]-n-ethyl-n-methylbenzenesulfonamide Chemical compound CCN(C)S(=O)(=O)C1=CC=CC=C1NC1=NC(NC=2C(=CC(=CC=2)N2CCOCC2)OC)=NC=C1Cl FJALCYJVUXODQN-UHFFFAOYSA-N 0.000 claims 1
- DXRFDAIKEGRWGE-UHFFFAOYSA-N 2-[[5-chloro-2-(2-methoxy-4-morpholin-4-ylanilino)pyrimidin-4-yl]amino]-n-methyl-n-(2-methylpropyl)benzenesulfonamide Chemical compound COC1=CC(N2CCOCC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1S(=O)(=O)N(C)CC(C)C DXRFDAIKEGRWGE-UHFFFAOYSA-N 0.000 claims 1
- GZTBQJVLFXFBPA-UHFFFAOYSA-N 2-[[5-chloro-2-(2-methoxy-4-morpholin-4-ylanilino)pyrimidin-4-yl]amino]-n-methyl-n-propan-2-ylbenzenesulfonamide Chemical compound COC1=CC(N2CCOCC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1S(=O)(=O)N(C)C(C)C GZTBQJVLFXFBPA-UHFFFAOYSA-N 0.000 claims 1
- OMBOTOFFZSYXJB-UHFFFAOYSA-N 2-[[5-chloro-2-(2-methoxy-4-morpholin-4-ylanilino)pyrimidin-4-yl]amino]-n-methyl-n-propylbenzenesulfonamide Chemical compound CCCN(C)S(=O)(=O)C1=CC=CC=C1NC1=NC(NC=2C(=CC(=CC=2)N2CCOCC2)OC)=NC=C1Cl OMBOTOFFZSYXJB-UHFFFAOYSA-N 0.000 claims 1
- DPNOHAJQDSAHNP-UHFFFAOYSA-N 2-[[5-chloro-2-(2-methoxy-5-morpholin-4-ylanilino)pyrimidin-4-yl]amino]-5-(4-hydroxypiperidin-1-yl)-n-methylbenzamide Chemical compound CNC(=O)C1=CC(N2CCC(O)CC2)=CC=C1NC(C(=CN=1)Cl)=NC=1NC(C(=CC=1)OC)=CC=1N1CCOCC1 DPNOHAJQDSAHNP-UHFFFAOYSA-N 0.000 claims 1
- NAVRVLFFTURNLG-UHFFFAOYSA-N 2-[[5-chloro-2-(2-methoxy-5-morpholin-4-ylanilino)pyrimidin-4-yl]amino]-n-(2-methylpropyl)benzenesulfonamide Chemical compound COC1=CC=C(N2CCOCC2)C=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1S(=O)(=O)NCC(C)C NAVRVLFFTURNLG-UHFFFAOYSA-N 0.000 claims 1
- HIIUXPYHIPMBLF-UHFFFAOYSA-N 2-[[5-chloro-2-(2-methoxy-5-morpholin-4-ylanilino)pyrimidin-4-yl]amino]-n-methyl-5-(4-methylpiperazin-1-yl)benzamide Chemical compound CNC(=O)C1=CC(N2CCN(C)CC2)=CC=C1NC(C(=CN=1)Cl)=NC=1NC(C(=CC=1)OC)=CC=1N1CCOCC1 HIIUXPYHIPMBLF-UHFFFAOYSA-N 0.000 claims 1
- OXJMYPXLFFRIBT-UHFFFAOYSA-N 2-[[5-chloro-2-[2-(cyclopropylmethoxy)-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]-n-propan-2-ylbenzenesulfonamide Chemical compound CC(C)NS(=O)(=O)C1=CC=CC=C1NC1=NC(NC=2C(=CC(=CC=2)N2CCN(C)CC2)OCC2CC2)=NC=C1Cl OXJMYPXLFFRIBT-UHFFFAOYSA-N 0.000 claims 1
- LBRVPGIXMBALBV-UHFFFAOYSA-N 2-[[5-chloro-2-[2-ethoxy-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]-n-propan-2-ylbenzenesulfonamide Chemical compound CCOC1=CC(N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1S(=O)(=O)NC(C)C LBRVPGIXMBALBV-UHFFFAOYSA-N 0.000 claims 1
- YCPIPRHAPNWBRT-UHFFFAOYSA-N 2-[[5-chloro-2-[2-methoxy-4-(1,2,2,6,6-pentamethylpiperidin-4-yl)oxyanilino]pyrimidin-4-yl]amino]-n-(2-methylpropyl)benzenesulfonamide Chemical compound C=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)NCC(C)C)C(Cl)=CN=2)C(OC)=CC=1OC1CC(C)(C)N(C)C(C)(C)C1 YCPIPRHAPNWBRT-UHFFFAOYSA-N 0.000 claims 1
- JSWCGIVZNHQNNP-UHFFFAOYSA-N 2-[[5-chloro-2-[2-methoxy-4-(1-methylpiperidin-4-yl)oxyanilino]pyrimidin-4-yl]amino]-n-(2-methylpropyl)benzenesulfonamide Chemical compound C=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)NCC(C)C)C(Cl)=CN=2)C(OC)=CC=1OC1CCN(C)CC1 JSWCGIVZNHQNNP-UHFFFAOYSA-N 0.000 claims 1
- BCQAJGPQDQTOGQ-UHFFFAOYSA-N 2-[[5-chloro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]-n-(2,2-dimethylpropyl)benzenesulfonamide Chemical compound COC1=CC(N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1S(=O)(=O)NCC(C)(C)C BCQAJGPQDQTOGQ-UHFFFAOYSA-N 0.000 claims 1
- USVFGRLWFJRBAO-UHFFFAOYSA-N 2-[[5-chloro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]-n-(2-methylpropyl)benzenesulfonamide Chemical compound COC1=CC(N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1S(=O)(=O)NCC(C)C USVFGRLWFJRBAO-UHFFFAOYSA-N 0.000 claims 1
- OAEOGENXYJSEMP-UHFFFAOYSA-N 2-[[5-chloro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]-n-ethyl-n-methylbenzenesulfonamide Chemical compound CCN(C)S(=O)(=O)C1=CC=CC=C1NC1=NC(NC=2C(=CC(=CC=2)N2CCN(C)CC2)OC)=NC=C1Cl OAEOGENXYJSEMP-UHFFFAOYSA-N 0.000 claims 1
- JABUPWYZDKDXQR-UHFFFAOYSA-N 2-[[5-chloro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]-n-methyl-n-(2-methylpropyl)benzenesulfonamide Chemical compound COC1=CC(N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1S(=O)(=O)N(C)CC(C)C JABUPWYZDKDXQR-UHFFFAOYSA-N 0.000 claims 1
- NDLGFBWRNSKIJK-UHFFFAOYSA-N 2-[[5-chloro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]-n-methyl-n-propylbenzenesulfonamide Chemical compound CCCN(C)S(=O)(=O)C1=CC=CC=C1NC1=NC(NC=2C(=CC(=CC=2)N2CCN(C)CC2)OC)=NC=C1Cl NDLGFBWRNSKIJK-UHFFFAOYSA-N 0.000 claims 1
- PNRBKALNMAMFQZ-UHFFFAOYSA-N 2-[[5-chloro-2-[2-methoxy-4-(4-piperidin-1-ylpiperidin-1-yl)anilino]pyrimidin-4-yl]amino]-n-(2-methylpropyl)benzenesulfonamide Chemical compound COC1=CC(N2CCC(CC2)N2CCCCC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1S(=O)(=O)NCC(C)C PNRBKALNMAMFQZ-UHFFFAOYSA-N 0.000 claims 1
- YDRQBSZVFZELQZ-UHFFFAOYSA-N 2-[[5-chloro-2-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]pyrimidin-4-yl]amino]-n-(2-methylpropyl)benzenesulfonamide Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1S(=O)(=O)NCC(C)C YDRQBSZVFZELQZ-UHFFFAOYSA-N 0.000 claims 1
- SAMQTWSCAPUSKT-LJQANCHMSA-N 2-[[5-chloro-2-[2-methoxy-4-[[(2r)-1-methylpyrrolidin-2-yl]methoxy]anilino]pyrimidin-4-yl]amino]-n-(2-methylpropyl)benzenesulfonamide Chemical compound C=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)NCC(C)C)C(Cl)=CN=2)C(OC)=CC=1OC[C@H]1CCCN1C SAMQTWSCAPUSKT-LJQANCHMSA-N 0.000 claims 1
- SAMQTWSCAPUSKT-IBGZPJMESA-N 2-[[5-chloro-2-[2-methoxy-4-[[(2s)-1-methylpyrrolidin-2-yl]methoxy]anilino]pyrimidin-4-yl]amino]-n-(2-methylpropyl)benzenesulfonamide Chemical compound C=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)NCC(C)C)C(Cl)=CN=2)C(OC)=CC=1OC[C@@H]1CCCN1C SAMQTWSCAPUSKT-IBGZPJMESA-N 0.000 claims 1
- HSEBUVIOAZVFMD-UHFFFAOYSA-N 2-[[5-chloro-2-[2-methoxy-5-(4-piperidin-1-ylpiperidin-1-yl)anilino]pyrimidin-4-yl]amino]-n-(2-methylpropyl)benzenesulfonamide Chemical compound COC1=CC=C(N2CCC(CC2)N2CCCCC2)C=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1S(=O)(=O)NCC(C)C HSEBUVIOAZVFMD-UHFFFAOYSA-N 0.000 claims 1
- SOMWMBIMDBWDCT-UHFFFAOYSA-N 2-[[5-chloro-2-[4-(4-hydroxypiperidin-1-yl)-2-methoxyanilino]pyrimidin-4-yl]amino]-n-(2-methylpropyl)benzenesulfonamide Chemical compound COC1=CC(N2CCC(O)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1S(=O)(=O)NCC(C)C SOMWMBIMDBWDCT-UHFFFAOYSA-N 0.000 claims 1
- SQLSWIIRAATDCE-UHFFFAOYSA-N 2-[[5-chloro-2-[4-(4-methylpiperazin-1-yl)-2-propan-2-yloxyanilino]pyrimidin-4-yl]amino]-n-propan-2-ylbenzenesulfonamide Chemical compound CC(C)NS(=O)(=O)C1=CC=CC=C1NC1=NC(NC=2C(=CC(=CC=2)N2CCN(C)CC2)OC(C)C)=NC=C1Cl SQLSWIIRAATDCE-UHFFFAOYSA-N 0.000 claims 1
- UYNUIILECCCRCI-QFIPXVFZSA-N 2-[[5-chloro-2-[4-[(3s)-3-(dimethylamino)pyrrolidin-1-yl]-2-methoxyanilino]pyrimidin-4-yl]amino]-n-methyl-5-(4-methylpiperazin-1-yl)benzamide Chemical compound CNC(=O)C1=CC(N2CCN(C)CC2)=CC=C1NC(C(=CN=1)Cl)=NC=1NC(C(=C1)OC)=CC=C1N1CC[C@H](N(C)C)C1 UYNUIILECCCRCI-QFIPXVFZSA-N 0.000 claims 1
- JQKFMPFDCPHZDC-UHFFFAOYSA-N 2-[[5-chloro-2-[5-[3-(dimethylamino)pyrrolidin-1-yl]-2-methoxyanilino]pyrimidin-4-yl]amino]-n-methyl-5-(4-methylpiperazin-1-yl)benzamide Chemical compound CNC(=O)C1=CC(N2CCN(C)CC2)=CC=C1NC(C(=CN=1)Cl)=NC=1NC(C(=CC=1)OC)=CC=1N1CCC(N(C)C)C1 JQKFMPFDCPHZDC-UHFFFAOYSA-N 0.000 claims 1
- QBYRJFAMUQFOTF-UHFFFAOYSA-N 3-[[5-chloro-4-[2-(2-methylpropylsulfamoyl)anilino]pyrimidin-2-yl]amino]-4-methoxy-n-methylbenzamide Chemical compound CNC(=O)C1=CC=C(OC)C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)NCC(C)C)C(Cl)=CN=2)=C1 QBYRJFAMUQFOTF-UHFFFAOYSA-N 0.000 claims 1
- WMMGZLDLOZGCCF-UHFFFAOYSA-N 3-[[5-chloro-4-[2-(2-methylpropylsulfamoyl)anilino]pyrimidin-2-yl]amino]-4-methoxybenzamide Chemical compound COC1=CC=C(C(N)=O)C=C1NC1=NC=C(Cl)C(NC=2C(=CC=CC=2)S(=O)(=O)NCC(C)C)=N1 WMMGZLDLOZGCCF-UHFFFAOYSA-N 0.000 claims 1
- IIQZMZQNOUYLPO-UHFFFAOYSA-N 4-[[5-chloro-4-[(1,1-dioxo-3,4-dihydro-2h-thiochromen-8-yl)amino]pyrimidin-2-yl]amino]-3-methoxy-n-methylbenzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(Cl)C(NC=2C=3S(=O)(=O)CCCC=3C=CC=2)=N1 IIQZMZQNOUYLPO-UHFFFAOYSA-N 0.000 claims 1
- BWJNPIJUMOBXIX-UHFFFAOYSA-N 4-[[5-chloro-4-[2-(2-methylpropylsulfamoyl)anilino]pyrimidin-2-yl]amino]-3-methoxy-n-methylbenzamide Chemical compound COC1=CC(C(=O)NC)=CC=C1NC1=NC=C(Cl)C(NC=2C(=CC=CC=2)S(=O)(=O)NCC(C)C)=N1 BWJNPIJUMOBXIX-UHFFFAOYSA-N 0.000 claims 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- RBNIGSMSNORUAO-UHFFFAOYSA-N 5-chloro-2-n-(2-methoxy-4-morpholin-4-ylphenyl)-4-n-(2-piperazin-1-ylsulfonylphenyl)pyrimidine-2,4-diamine Chemical compound COC1=CC(N2CCOCC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1S(=O)(=O)N1CCNCC1 RBNIGSMSNORUAO-UHFFFAOYSA-N 0.000 claims 1
- IFYVVWPOUKNORV-UHFFFAOYSA-N 5-chloro-2-n-(2-methoxy-4-morpholin-4-ylphenyl)-4-n-[2-(2h-tetrazol-5-yl)phenyl]pyrimidine-2,4-diamine Chemical compound COC1=CC(N2CCOCC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1C=1N=NNN=1 IFYVVWPOUKNORV-UHFFFAOYSA-N 0.000 claims 1
- UPRPZDNVKIJCPZ-UHFFFAOYSA-N 5-chloro-2-n-(2-methoxy-4-morpholin-4-ylphenyl)-4-n-[2-(4-methylpiperazin-1-yl)sulfonylphenyl]pyrimidine-2,4-diamine Chemical compound COC1=CC(N2CCOCC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1S(=O)(=O)N1CCN(C)CC1 UPRPZDNVKIJCPZ-UHFFFAOYSA-N 0.000 claims 1
- LROJRYFDOVZSKF-IBGZPJMESA-N 5-chloro-2-n-[4-[(3s)-3-(dimethylamino)pyrrolidin-1-yl]-2-methoxyphenyl]-4-n-(1,1-dioxo-3,4-dihydro-2h-thiochromen-8-yl)pyrimidine-2,4-diamine Chemical compound C=1C=C(NC=2N=C(NC=3C=4S(=O)(=O)CCCC=4C=CC=3)C(Cl)=CN=2)C(OC)=CC=1N1CC[C@H](N(C)C)C1 LROJRYFDOVZSKF-IBGZPJMESA-N 0.000 claims 1
- JCGLVTFJKQWQLM-UHFFFAOYSA-N 5-chloro-2-n-[4-[4-(4-ethylpiperazin-1-yl)piperidin-1-yl]-2-methoxyphenyl]-4-n-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine Chemical compound C1CN(CC)CCN1C1CCN(C=2C=C(OC)C(NC=3N=C(NC=4C(=CC=CC=4)S(=O)(=O)C(C)C)C(Cl)=CN=3)=CC=2)CC1 JCGLVTFJKQWQLM-UHFFFAOYSA-N 0.000 claims 1
- GGBAQRBKKXXBGB-UHFFFAOYSA-N 7-[[5-chloro-2-(2,4-dimethoxyanilino)pyrimidin-4-yl]amino]-2-methyl-3h-isoindol-1-one Chemical compound COC1=CC(OC)=CC=C1NC1=NC=C(Cl)C(NC=2C=3C(=O)N(C)CC=3C=CC=2)=N1 GGBAQRBKKXXBGB-UHFFFAOYSA-N 0.000 claims 1
- DMDITBMGBBYVFF-UHFFFAOYSA-N 7-[[5-chloro-2-[2-methoxy-4-(1-methylpiperidin-4-yl)oxyanilino]pyrimidin-4-yl]amino]-2-methyl-3h-isoindol-1-one Chemical compound C=1C=C(NC=2N=C(NC=3C=4C(=O)N(C)CC=4C=CC=3)C(Cl)=CN=2)C(OC)=CC=1OC1CCN(C)CC1 DMDITBMGBBYVFF-UHFFFAOYSA-N 0.000 claims 1
- CADMEIKYCXXWFH-UHFFFAOYSA-N 7-[[5-chloro-2-[2-methoxy-4-(1-propan-2-ylpiperidin-4-yl)oxyanilino]pyrimidin-4-yl]amino]-2-methyl-3h-isoindol-1-one Chemical compound C=1C=C(NC=2N=C(NC=3C=4C(=O)N(C)CC=4C=CC=3)C(Cl)=CN=2)C(OC)=CC=1OC1CCN(C(C)C)CC1 CADMEIKYCXXWFH-UHFFFAOYSA-N 0.000 claims 1
- NUEWPUVJYFLCDB-UHFFFAOYSA-N 7-[[5-chloro-2-[2-methoxy-4-(2-morpholin-4-ylethoxy)anilino]pyrimidin-4-yl]amino]-2-methyl-3h-isoindol-1-one Chemical compound C=1C=C(NC=2N=C(NC=3C=4C(=O)N(C)CC=4C=CC=3)C(Cl)=CN=2)C(OC)=CC=1OCCN1CCOCC1 NUEWPUVJYFLCDB-UHFFFAOYSA-N 0.000 claims 1
- QBWMUEXYDNIHHL-UHFFFAOYSA-N 7-[[5-chloro-2-[2-methoxy-4-(2-piperidin-1-ylethoxy)anilino]pyrimidin-4-yl]amino]-2-methyl-3h-isoindol-1-one Chemical compound C=1C=C(NC=2N=C(NC=3C=4C(=O)N(C)CC=4C=CC=3)C(Cl)=CN=2)C(OC)=CC=1OCCN1CCCCC1 QBWMUEXYDNIHHL-UHFFFAOYSA-N 0.000 claims 1
- VOVSNCDBZVROQM-UHFFFAOYSA-N 7-[[5-chloro-2-[2-methoxy-4-(4-piperidin-1-ylpiperidin-1-yl)anilino]pyrimidin-4-yl]amino]-2-methyl-3h-isoindol-1-one Chemical compound C=1C=C(NC=2N=C(NC=3C=4C(=O)N(C)CC=4C=CC=3)C(Cl)=CN=2)C(OC)=CC=1N(CC1)CCC1N1CCCCC1 VOVSNCDBZVROQM-UHFFFAOYSA-N 0.000 claims 1
- DERQOGVPZIAENT-UHFFFAOYSA-N 7-[[5-chloro-2-[2-methoxy-4-(4-propan-2-ylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]-2-methyl-3h-isoindol-1-one Chemical compound C=1C=C(NC=2N=C(NC=3C=4C(=O)N(C)CC=4C=CC=3)C(Cl)=CN=2)C(OC)=CC=1N1CCN(C(C)C)CC1 DERQOGVPZIAENT-UHFFFAOYSA-N 0.000 claims 1
- FYLWWAARLSGYSK-GOSISDBHSA-N 7-[[5-chloro-2-[2-methoxy-4-[(3r)-4-(2-methoxyethyl)-3-methylpiperazin-1-yl]anilino]pyrimidin-4-yl]amino]-2-methyl-3h-isoindol-1-one Chemical compound C1[C@@H](C)N(CCOC)CCN1C(C=C1OC)=CC=C1NC1=NC=C(Cl)C(NC=2C=3C(=O)N(C)CC=3C=CC=2)=N1 FYLWWAARLSGYSK-GOSISDBHSA-N 0.000 claims 1
- FYLWWAARLSGYSK-SFHVURJKSA-N 7-[[5-chloro-2-[2-methoxy-4-[(3s)-4-(2-methoxyethyl)-3-methylpiperazin-1-yl]anilino]pyrimidin-4-yl]amino]-2-methyl-3h-isoindol-1-one Chemical compound C1[C@H](C)N(CCOC)CCN1C(C=C1OC)=CC=C1NC1=NC=C(Cl)C(NC=2C=3C(=O)N(C)CC=3C=CC=2)=N1 FYLWWAARLSGYSK-SFHVURJKSA-N 0.000 claims 1
- UUNLSAZLCKGHCM-UHFFFAOYSA-N 7-[[5-chloro-2-[2-methoxy-4-[2-(4-methylpiperazin-1-yl)ethoxy]anilino]pyrimidin-4-yl]amino]-2-methyl-3h-isoindol-1-one Chemical compound C=1C=C(NC=2N=C(NC=3C=4C(=O)N(C)CC=4C=CC=3)C(Cl)=CN=2)C(OC)=CC=1OCCN1CCN(C)CC1 UUNLSAZLCKGHCM-UHFFFAOYSA-N 0.000 claims 1
- IWUBJKFDSRXWIG-UHFFFAOYSA-N 7-[[5-chloro-2-[2-methoxy-4-[2-(4-propan-2-ylpiperazin-1-yl)ethoxy]anilino]pyrimidin-4-yl]amino]-2-methyl-3h-isoindol-1-one Chemical compound C=1C=C(NC=2N=C(NC=3C=4C(=O)N(C)CC=4C=CC=3)C(Cl)=CN=2)C(OC)=CC=1OCCN1CCN(C(C)C)CC1 IWUBJKFDSRXWIG-UHFFFAOYSA-N 0.000 claims 1
- TZUPKPQHKQRRSE-UHFFFAOYSA-N 7-[[5-chloro-2-[2-methoxy-4-[3-(4-methylpiperazin-1-yl)propoxy]anilino]pyrimidin-4-yl]amino]-2-methyl-3h-isoindol-1-one Chemical compound C=1C=C(NC=2N=C(NC=3C=4C(=O)N(C)CC=4C=CC=3)C(Cl)=CN=2)C(OC)=CC=1OCCCN1CCN(C)CC1 TZUPKPQHKQRRSE-UHFFFAOYSA-N 0.000 claims 1
- AQYBYIXXQKEJOH-UHFFFAOYSA-N 7-[[5-chloro-2-[2-methoxy-5-(2-morpholin-4-ylethoxy)anilino]pyrimidin-4-yl]amino]-2-methyl-3h-isoindol-1-one Chemical compound C1=C(NC=2N=C(NC=3C=4C(=O)N(C)CC=4C=CC=3)C(Cl)=CN=2)C(OC)=CC=C1OCCN1CCOCC1 AQYBYIXXQKEJOH-UHFFFAOYSA-N 0.000 claims 1
- ZDZQUXQJIQLSNY-GOSISDBHSA-N 7-[[5-chloro-2-[4-[(3r)-3-(dimethylamino)pyrrolidin-1-yl]-2-methoxyanilino]pyrimidin-4-yl]amino]-2-methyl-3h-isoindol-1-one Chemical compound C=1C=C(NC=2N=C(NC=3C=4C(=O)N(C)CC=4C=CC=3)C(Cl)=CN=2)C(OC)=CC=1N1CC[C@@H](N(C)C)C1 ZDZQUXQJIQLSNY-GOSISDBHSA-N 0.000 claims 1
- ZDZQUXQJIQLSNY-SFHVURJKSA-N 7-[[5-chloro-2-[4-[(3s)-3-(dimethylamino)pyrrolidin-1-yl]-2-methoxyanilino]pyrimidin-4-yl]amino]-2-methyl-3h-isoindol-1-one Chemical compound C=1C=C(NC=2N=C(NC=3C=4C(=O)N(C)CC=4C=CC=3)C(Cl)=CN=2)C(OC)=CC=1N1CC[C@H](N(C)C)C1 ZDZQUXQJIQLSNY-SFHVURJKSA-N 0.000 claims 1
- BHKVOPHQQWFCRG-UHFFFAOYSA-N 7-[[5-chloro-2-[4-[2-(4-hydroxypiperidin-1-yl)ethoxy]-2-methoxyanilino]pyrimidin-4-yl]amino]-2-methyl-3h-isoindol-1-one Chemical compound C=1C=C(NC=2N=C(NC=3C=4C(=O)N(C)CC=4C=CC=3)C(Cl)=CN=2)C(OC)=CC=1OCCN1CCC(O)CC1 BHKVOPHQQWFCRG-UHFFFAOYSA-N 0.000 claims 1
- GXQPCESPVQJQPA-HXUWFJFHSA-N 8-[[2-[4-[(9ar)-3,4,6,7,9,9a-hexahydro-1h-pyrazino[2,1-c][1,4]oxazin-8-yl]-2-methoxyanilino]-5-chloropyrimidin-4-yl]amino]-2-methyl-3,4-dihydroisoquinolin-1-one Chemical compound C1CN2CCOC[C@H]2CN1C1=CC=C(NC=2N=C(NC=3C=4C(=O)N(C)CCC=4C=CC=3)C(Cl)=CN=2)C(OC)=C1 GXQPCESPVQJQPA-HXUWFJFHSA-N 0.000 claims 1
- GXQPCESPVQJQPA-FQEVSTJZSA-N 8-[[2-[4-[(9as)-3,4,6,7,9,9a-hexahydro-1h-pyrazino[2,1-c][1,4]oxazin-8-yl]-2-methoxyanilino]-5-chloropyrimidin-4-yl]amino]-2-methyl-3,4-dihydroisoquinolin-1-one Chemical compound C1CN2CCOC[C@@H]2CN1C1=CC=C(NC=2N=C(NC=3C=4C(=O)N(C)CCC=4C=CC=3)C(Cl)=CN=2)C(OC)=C1 GXQPCESPVQJQPA-FQEVSTJZSA-N 0.000 claims 1
- CCTCVOLEBOWMOS-UHFFFAOYSA-N 8-[[5-chloro-2-(2-methoxy-4-morpholin-4-ylanilino)pyrimidin-4-yl]amino]-2-ethyl-3,4-dihydroisoquinolin-1-one Chemical compound C=12C(=O)N(CC)CCC2=CC=CC=1NC(C(=CN=1)Cl)=NC=1NC(C(=C1)OC)=CC=C1N1CCOCC1 CCTCVOLEBOWMOS-UHFFFAOYSA-N 0.000 claims 1
- JLJSDGVDKYIZRL-UHFFFAOYSA-N 8-[[5-chloro-2-(2-methoxy-4-morpholin-4-ylanilino)pyrimidin-4-yl]amino]-2-methyl-3,4-dihydroisoquinolin-1-one Chemical compound C=1C=C(NC=2N=C(NC=3C=4C(=O)N(C)CCC=4C=CC=3)C(Cl)=CN=2)C(OC)=CC=1N1CCOCC1 JLJSDGVDKYIZRL-UHFFFAOYSA-N 0.000 claims 1
- KJZBORGJNWIIQP-UHFFFAOYSA-N 8-[[5-chloro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]-2-methyl-3,4-dihydroisoquinolin-1-one Chemical compound C=1C=C(NC=2N=C(NC=3C=4C(=O)N(C)CCC=4C=CC=3)C(Cl)=CN=2)C(OC)=CC=1N1CCN(C)CC1 KJZBORGJNWIIQP-UHFFFAOYSA-N 0.000 claims 1
- JCPQASIDBXUWGJ-UHFFFAOYSA-N 8-[[5-chloro-2-[2-methoxy-4-(4-propan-2-ylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]-2-methyl-3,4-dihydroisoquinolin-1-one Chemical compound C=1C=C(NC=2N=C(NC=3C=4C(=O)N(C)CCC=4C=CC=3)C(Cl)=CN=2)C(OC)=CC=1N1CCN(C(C)C)CC1 JCPQASIDBXUWGJ-UHFFFAOYSA-N 0.000 claims 1
- JROJTMZAKOEVOX-UHFFFAOYSA-N 8-[[5-chloro-2-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]pyrimidin-4-yl]amino]-2-ethyl-3,4-dihydroisoquinolin-1-one Chemical compound C=12C(=O)N(CC)CCC2=CC=CC=1NC(C(=CN=1)Cl)=NC=1NC(C(=C1)OC)=CC=C1N(CC1)CCC1N1CCN(C)CC1 JROJTMZAKOEVOX-UHFFFAOYSA-N 0.000 claims 1
- VRBQCRJAYXBEJP-UHFFFAOYSA-N 8-[[5-chloro-2-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]pyrimidin-4-yl]amino]-2-methyl-3,4-dihydroisoquinolin-1-one Chemical compound C=1C=C(NC=2N=C(NC=3C=4C(=O)N(C)CCC=4C=CC=3)C(Cl)=CN=2)C(OC)=CC=1N(CC1)CCC1N1CCN(C)CC1 VRBQCRJAYXBEJP-UHFFFAOYSA-N 0.000 claims 1
- OVNQEFQSYGUPMZ-UHFFFAOYSA-N 8-[[5-chloro-2-[4-(4-hydroxypiperidin-1-yl)-2-methoxyanilino]pyrimidin-4-yl]amino]-2-methyl-3,4-dihydroisoquinolin-1-one Chemical compound C=1C=C(NC=2N=C(NC=3C=4C(=O)N(C)CCC=4C=CC=3)C(Cl)=CN=2)C(OC)=CC=1N1CCC(O)CC1 OVNQEFQSYGUPMZ-UHFFFAOYSA-N 0.000 claims 1
- AYEVKVJHBPXJNM-LJQANCHMSA-N 8-[[5-chloro-2-[4-[(3r)-3-(dimethylamino)pyrrolidin-1-yl]-2-methoxyanilino]pyrimidin-4-yl]amino]-2-methyl-3,4-dihydroisoquinolin-1-one Chemical compound C=1C=C(NC=2N=C(NC=3C=4C(=O)N(C)CCC=4C=CC=3)C(Cl)=CN=2)C(OC)=CC=1N1CC[C@@H](N(C)C)C1 AYEVKVJHBPXJNM-LJQANCHMSA-N 0.000 claims 1
- AYEVKVJHBPXJNM-IBGZPJMESA-N 8-[[5-chloro-2-[4-[(3s)-3-(dimethylamino)pyrrolidin-1-yl]-2-methoxyanilino]pyrimidin-4-yl]amino]-2-methyl-3,4-dihydroisoquinolin-1-one Chemical compound C=1C=C(NC=2N=C(NC=3C=4C(=O)N(C)CCC=4C=CC=3)C(Cl)=CN=2)C(OC)=CC=1N1CC[C@H](N(C)C)C1 AYEVKVJHBPXJNM-IBGZPJMESA-N 0.000 claims 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims 1
- 102000038455 IGF Type 1 Receptor Human genes 0.000 claims 1
- 108010031794 IGF Type 1 Receptor Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000037841 lung tumor Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000014500 neuronal tumor Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 208000023958 prostate neoplasm Diseases 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 208000013076 thyroid tumor Diseases 0.000 claims 1
- 208000025421 tumor of uterus Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0419161.5A GB0419161D0 (en) | 2004-08-27 | 2004-08-27 | Organic compounds |
| PCT/EP2005/009251 WO2006021454A2 (en) | 2004-08-27 | 2005-08-26 | Pyrimidine derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008510763A JP2008510763A (ja) | 2008-04-10 |
| JP2008510763A5 true JP2008510763A5 (https=) | 2008-10-09 |
Family
ID=33104746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007528754A Pending JP2008510763A (ja) | 2004-08-27 | 2005-08-26 | ピリミジン誘導体 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20090131436A1 (https=) |
| EP (1) | EP1784392A2 (https=) |
| JP (1) | JP2008510763A (https=) |
| KR (1) | KR20070054223A (https=) |
| CN (1) | CN101048386A (https=) |
| AR (1) | AR054081A1 (https=) |
| AU (1) | AU2005276582B2 (https=) |
| BR (1) | BRPI0514681A (https=) |
| CA (1) | CA2577251A1 (https=) |
| EC (1) | ECSP077271A (https=) |
| GB (1) | GB0419161D0 (https=) |
| GT (1) | GT200500237A (https=) |
| HR (1) | HRP20070076A2 (https=) |
| IL (1) | IL181433A0 (https=) |
| MA (1) | MA28824B1 (https=) |
| MX (1) | MX2007002254A (https=) |
| NO (1) | NO20071593L (https=) |
| PE (1) | PE20060622A1 (https=) |
| RU (1) | RU2401260C2 (https=) |
| TN (1) | TNSN07075A1 (https=) |
| TW (1) | TW200621729A (https=) |
| WO (1) | WO2006021454A2 (https=) |
| ZA (1) | ZA200701406B (https=) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| ES2445208T3 (es) | 2002-07-29 | 2014-02-28 | Rigel Pharmaceuticals, Inc. | Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias |
| BRPI0413018B8 (pt) | 2003-07-30 | 2021-05-25 | Rigel Pharmaceuticals Inc | composto, e, uso de um composto |
| US7521457B2 (en) * | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
| AU2005322855B2 (en) * | 2004-12-30 | 2012-09-20 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
| WO2007028445A1 (en) * | 2005-07-15 | 2007-03-15 | Glaxo Group Limited | 6-indolyl-4-yl-amino-5-halogeno-2-pyrimidinyl-amino derivatives |
| GB0517329D0 (en) * | 2005-08-25 | 2005-10-05 | Merck Sharp & Dohme | Stimulation of neurogenesis |
| US8168383B2 (en) | 2006-04-14 | 2012-05-01 | Cell Signaling Technology, Inc. | Gene defects and mutant ALK kinase in human solid tumors |
| EP2450437B1 (en) | 2006-04-14 | 2017-05-17 | Cell Signaling Technology, Inc. | Gene defects and mutant ALK kinase in human solid tumors |
| EP2043651A2 (en) | 2006-07-05 | 2009-04-08 | Exelixis, Inc. | Methods of using igf1r and abl kinase modulators |
| CN101535276B (zh) | 2006-10-23 | 2013-08-28 | 赛福伦公司 | 作为ALK和c-MET抑制剂的2,4-二氨基嘧啶稠合双环衍生物 |
| EP2311807B1 (en) * | 2006-12-08 | 2015-11-11 | Novartis AG | Compounds and composition as protein kinase inhibitors |
| BRPI0720264B1 (pt) * | 2006-12-08 | 2022-03-03 | Novartis Ag | Compostos e composições como inibidores de proteína cinase |
| CA2670645A1 (en) * | 2006-12-19 | 2008-07-03 | Genentech, Inc. | Pyrimidine kinase inhibitors |
| AR065015A1 (es) | 2007-01-26 | 2009-05-13 | Smithkline Beecham Corp | Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer |
| US7947698B2 (en) | 2007-03-23 | 2011-05-24 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
| US9409886B2 (en) | 2007-07-05 | 2016-08-09 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| CN103396409B (zh) | 2007-07-05 | 2015-03-11 | 阵列生物制药公司 | 作为akt蛋白激酶抑制剂的嘧啶基环戊烷 |
| TWI389893B (zh) | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | 二（芳胺基）芳基化合物 |
| EP2183242A2 (en) * | 2007-07-16 | 2010-05-12 | AstraZeneca AB | Pyrimidine derivatives 934 |
| US8592432B2 (en) | 2008-04-07 | 2013-11-26 | Bei Chen | Compounds and compositions as protein kinase inhibitors |
| WO2009127642A2 (en) * | 2008-04-15 | 2009-10-22 | Cellzome Limited | Use of lrrk2 inhibitors for neurodegenerative diseases |
| PT2300013T (pt) | 2008-05-21 | 2017-10-31 | Ariad Pharma Inc | Derivados de fósforo como inibidores de cinases |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| MX2010014057A (es) | 2008-06-17 | 2011-03-21 | Astrazeneca Ab | Compuestos de piridina. |
| US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| TWI546290B (zh) | 2008-06-27 | 2016-08-21 | 賽基艾維洛米斯研究股份有限公司 | 雜芳基化合物及其用途 |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| JO3067B1 (ar) * | 2008-10-27 | 2017-03-15 | Glaxosmithkline Llc | بيرميدينات بيرازولو امينو كمثبطات ل fak |
| US8278084B2 (en) | 2009-02-11 | 2012-10-02 | Northwestern University | Aminopyridine dimer compounds, compositions and related methods for neuronal nitric oxide synthase inhibition |
| US8932842B2 (en) | 2009-02-11 | 2015-01-13 | Northwestern University | Aminopyridine dimer compounds, compositions and related methods for neuronal nitric oxide synthase inhibition |
| KR101705158B1 (ko) | 2009-05-05 | 2017-02-09 | 다나-파버 캔서 인스티튜트 인크. | Ｅｇｆｒ 억제제 및 질환 치료방법 |
| MX2011012632A (es) * | 2009-05-27 | 2012-03-06 | Abbott Lab | Inhibidores de actividad de cinasa tipo pirimidina. |
| TW201100441A (en) | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
| CA2763717A1 (en) * | 2009-06-10 | 2010-12-16 | Cellzome Limited | Pyrimidine derivatives as zap-70 inhibitors |
| US20120165332A1 (en) * | 2009-06-18 | 2012-06-28 | Cellzome Limited | Sulfonamides and sulfamides as zap-70 inhibitors |
| CN105566229A (zh) | 2010-08-10 | 2016-05-11 | 西建阿维拉米斯研究公司 | Btk抑制剂的苯磺酸盐及其用途和制备方法 |
| MX382354B (es) | 2010-11-01 | 2025-03-13 | Celgene Car Llc | Compuestos heterocíclicos y usos de los mismos. |
| EP2635285B1 (en) | 2010-11-01 | 2017-05-03 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| JP5957003B2 (ja) | 2010-11-10 | 2016-07-27 | セルジーン アヴィロミクス リサーチ， インコーポレイテッド | 変異体選択的ｅｇｆｒ阻害剤およびその使用 |
| US9133224B2 (en) | 2010-11-29 | 2015-09-15 | OSI Pharmaceuticals, LLC | Macrocyclic kinase inhibitors |
| CN103282359A (zh) * | 2010-12-17 | 2013-09-04 | 诺华股份有限公司 | 5-氯-n2-(2-异丙氧基-5-甲基-4-哌啶-4-基-苯基)-n4-[2-(丙烷-2-磺酰基)-苯基]-嘧啶-2,4-二胺的结晶形式 |
| US8546443B2 (en) * | 2010-12-21 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Benzylic oxindole pyrimidines |
| MX2013008791A (es) * | 2011-02-02 | 2013-10-07 | Irm Llc | Metodos para usar inhibidores de alk. |
| EP2675793B1 (en) | 2011-02-17 | 2018-08-08 | Cancer Therapeutics Crc Pty Limited | Fak inhibitors |
| JP5937112B2 (ja) | 2011-02-17 | 2016-06-22 | カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドＣａｎｃｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｒｃ Ｐｔｙ Ｌｉｍｉｔｅｄ | 選択的ｆａｋ阻害剤 |
| US9834518B2 (en) | 2011-05-04 | 2017-12-05 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| WO2012175711A1 (en) * | 2011-06-24 | 2012-12-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for predicting the responsiveness of a patient affected with an osteosarcoma to a chemotherapy |
| AR088570A1 (es) | 2011-10-28 | 2014-06-18 | Celgene Avilomics Res Inc | Metodos para tratar una enfermedad o trastorno relacionado con la tirosina quinasa de bruton |
| KR102081042B1 (ko) | 2012-03-15 | 2020-02-26 | 셀젠 카르 엘엘씨 | 상피 성장 인자 수용체 키나제 억제제의 고체 형태 |
| PL2825042T3 (pl) | 2012-03-15 | 2019-02-28 | Celgene Car Llc | Sole inhibitora kinazy receptora czynnika wzrostu naskórka |
| US20150166591A1 (en) | 2012-05-05 | 2015-06-18 | Ariad Pharmaceuticals, Inc. | Methods and compositions for raf kinase mediated diseases |
| KR101582852B1 (ko) * | 2012-05-24 | 2016-01-07 | 서울대학교 산학협력단 | 타우 단백질 매개 신경 퇴행성 질환 치료제 |
| KR101446742B1 (ko) * | 2012-08-10 | 2014-10-01 | 한국화학연구원 | Ｎ2,ｎ4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| BR112015010221B1 (pt) * | 2012-11-06 | 2022-09-13 | Shanghai Fochon Pharmaceutical Co., Ltd. | Inibidores de quinase alk, seus usos, composição farmacêutica, e método para fabricação de medicamento |
| US9126950B2 (en) | 2012-12-21 | 2015-09-08 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| AU2014214846A1 (en) | 2013-02-08 | 2015-07-23 | Celgene Avilomics Research, Inc. | ERK inhibitors and uses thereof |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| CN104109149B (zh) * | 2013-04-22 | 2018-09-28 | 苏州泽璟生物制药有限公司 | 氘代的二氨基嘧啶化合物以及包含该化合物的药物组合物 |
| US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
| US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| WO2015117087A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
| CA2936865A1 (en) * | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Diaminopyrimidine benzenesulfone derivatives and uses thereof |
| CN106715437A (zh) | 2014-08-08 | 2017-05-24 | 达纳-法伯癌症研究所股份有限公司 | 二氮杂环庚烷衍生物及其用途 |
| US10005760B2 (en) | 2014-08-13 | 2018-06-26 | Celgene Car Llc | Forms and compositions of an ERK inhibitor |
| EP3265455B1 (en) * | 2015-03-04 | 2020-07-15 | Novartis AG | Process for preparing ceritinib and intermediates thereof |
| CN106146525B (zh) * | 2015-04-10 | 2018-11-02 | 山东轩竹医药科技有限公司 | 三并环类间变性淋巴瘤激酶抑制剂 |
| US10702527B2 (en) | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| CZ2015613A3 (cs) | 2015-09-09 | 2017-03-22 | Zentiva, K.S. | Způsob přípravy Ceritinibu |
| HK1256417A1 (zh) | 2015-09-11 | 2019-09-20 | 达纳-法伯癌症研究所股份有限公司 | 氰基噻吩并三唑并二氮杂环庚三烯及其用途 |
| RU2018112953A (ru) | 2015-09-11 | 2019-10-14 | Дана-Фарбер Кэнсер Инститьют, Инк. | Ацетамидтиенотриазолодиазепины и пути их применения |
| CN106699743B (zh) * | 2015-11-05 | 2020-06-12 | 湖北生物医药产业技术研究院有限公司 | 嘧啶类衍生物及其用途 |
| MX2018006499A (es) | 2015-11-25 | 2018-08-01 | Dana Farber Cancer Inst Inc | Inhibidores de bromodominio bivalentes y usos de los mismos. |
| CN106905303A (zh) * | 2017-03-16 | 2017-06-30 | 北京师范大学 | 一类靶向fak的化合物和其标记物、及它们的制备方法和应用 |
| WO2019007293A1 (zh) * | 2017-07-01 | 2019-01-10 | 浙江同源康医药股份有限公司 | 用作alk激酶抑制剂的化合物及其应用 |
| CN108047204A (zh) * | 2018-01-08 | 2018-05-18 | 沈阳药科大学 | 2,4-二芳氨基嘧啶衍生物及其制备方法和应用 |
| CN110835320B (zh) * | 2018-08-15 | 2025-12-30 | 江苏奥赛康药业有限公司 | 二氨基嘧啶类化合物及其应用 |
| JP2022539208A (ja) | 2019-07-03 | 2022-09-07 | スミトモ ファーマ オンコロジー， インコーポレイテッド | チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用 |
| WO2021113689A1 (en) * | 2019-12-06 | 2021-06-10 | Yale University | Spak/osr inhibitors and methods of using same |
| WO2022147622A1 (en) * | 2021-01-07 | 2022-07-14 | Ontario Institute For Cancer Research (Oicr) | Isoindolinone aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof |
| CN119264116B (zh) * | 2024-09-27 | 2025-09-23 | 安徽中医药大学 | 一种cdk6/9双重抑制剂及其制备方法与用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0004890D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| WO2003030909A1 (en) * | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| GB0206215D0 (en) * | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| WO2003095448A1 (en) * | 2002-05-06 | 2003-11-20 | Bayer Pharmaceuticals Corporation | Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders |
| GB0305929D0 (en) * | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| NZ585188A (en) * | 2003-08-15 | 2011-09-30 | Novartis Ag | 2,4-Pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
| MXPA06003054A (es) * | 2003-09-18 | 2006-05-31 | Novartis Ag | 2,4-di-(fenil-amino)-pirimidinas utiles en el tratamiento de trastornos proliferativos. |
| GB0419160D0 (en) * | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
-
2004
- 2004-08-27 GB GBGB0419161.5A patent/GB0419161D0/en not_active Ceased
-
2005
- 2005-08-25 PE PE2005000982A patent/PE20060622A1/es not_active Application Discontinuation
- 2005-08-26 AU AU2005276582A patent/AU2005276582B2/en not_active Ceased
- 2005-08-26 US US11/574,019 patent/US20090131436A1/en not_active Abandoned
- 2005-08-26 JP JP2007528754A patent/JP2008510763A/ja active Pending
- 2005-08-26 TW TW094129176A patent/TW200621729A/zh unknown
- 2005-08-26 AR ARP050103592A patent/AR054081A1/es not_active Application Discontinuation
- 2005-08-26 RU RU2007110950/04A patent/RU2401260C2/ru not_active IP Right Cessation
- 2005-08-26 HR HR20070076A patent/HRP20070076A2/xx not_active Application Discontinuation
- 2005-08-26 CN CNA2005800368883A patent/CN101048386A/zh active Pending
- 2005-08-26 BR BRPI0514681-0A patent/BRPI0514681A/pt not_active IP Right Cessation
- 2005-08-26 MX MX2007002254A patent/MX2007002254A/es active IP Right Grant
- 2005-08-26 EP EP05776772A patent/EP1784392A2/en not_active Withdrawn
- 2005-08-26 CA CA002577251A patent/CA2577251A1/en not_active Abandoned
- 2005-08-26 KR KR1020077006800A patent/KR20070054223A/ko not_active Ceased
- 2005-08-26 WO PCT/EP2005/009251 patent/WO2006021454A2/en not_active Ceased
- 2005-08-31 GT GT200500237A patent/GT200500237A/es unknown
-
2007
- 2007-02-15 ZA ZA200701406A patent/ZA200701406B/xx unknown
- 2007-02-19 IL IL181433A patent/IL181433A0/en unknown
- 2007-02-23 MA MA29714A patent/MA28824B1/fr unknown
- 2007-02-23 EC EC2007007271A patent/ECSP077271A/es unknown
- 2007-02-26 TN TNP2007000075A patent/TNSN07075A1/en unknown
- 2007-03-27 NO NO20071593A patent/NO20071593L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008510763A5 (https=) | ||
| RU2007110950A (ru) | Пиримидиновые производные | |
| AU2015303641B2 (en) | 2-(2,4,5-substituted aniline) pyrimidine derivative, pharmaceutical composition and use thereof | |
| JP2016525509A5 (https=) | ||
| ES2924915T3 (es) | Inhibidores de RHO cinasa | |
| RU2016103938A (ru) | Модуляторы протеин-тирозинкиназы и способы их применения | |
| IL271291B2 (en) | History of n2,n4-diphenylpyrimidine-2,4-diamine, a method for their preparation, and a pharmaceutical preparation containing them as an active ingredient for the prevention or treatment of cancer | |
| US10342796B2 (en) | Acrylanilide derivative, preparation method, and applications thereof in pharmacy | |
| US8703787B2 (en) | Methods of using ALK inhibitors | |
| CN114430740A (zh) | Egfr抑制剂、组合物及其制备方法 | |
| BR112014026383B1 (pt) | derivados de benzamida, seu uso, e composição farmacêutica | |
| ES2986889T3 (es) | Compuesto pirimidina sustituido con 2,4-di-(grupo nitrogenado) y método de preparación y uso del mismo | |
| PT2428508E (pt) | Composto diamino-carboxamida heterocíclico | |
| JP2011515462A5 (https=) | ||
| JP2009541311A5 (https=) | ||
| CA2518932A1 (en) | 2,4-di(phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | |
| CN103269701A (zh) | 用于治疗野生型egfr和/或kras患者的非小细胞肺癌的hsp90抑制剂 | |
| JP6795518B2 (ja) | キナーゼを阻害する組成物及び方法 | |
| US20150313900A1 (en) | Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity | |
| MX2007001696A (es) | Analogos de biaril piperazinil-piridina substituidos. | |
| JP2017536342A5 (https=) | ||
| JP2016520637A5 (https=) | ||
| JP7737117B2 (ja) | タンパク質キナーゼに対する阻害活性を有するピリミジン誘導体及びそれを含む治療用医薬組成物 | |
| JP2009537606A5 (https=) | ||
| US20030114463A1 (en) | Tetrahydroindolone and purine derivatives linked to arylpiperazines |